Resolution of the 1st Ukrainian expert forum on abnormal uterine bleeding

On April 20, 2021, the Ukrainian Expert Forum on Abnormal Uterine Bleeding was held.


  • -



resolution, Association of Gynecologists-Endocrinologists of Ukraine, Ukrainian Expert Forum on Abnormal Uterine Bleeding, abnormal uterine bleeding


The menstrual cycle is an important indicator not only of the female reproductive system health but also an integral part of women's health. The issues of therapeutic approaches for menstrual disorders, considering the general trend towards an increase in the proportion of this pathology among the total gynecological disorders in Ukraine, are susceptible and require close attention. The problem of abnormal uterine bleeding (AUB) has a significant impact on women and health care worldwide. Algorithms for the diagnosis and therapy of AUB need to be regularly revised as international recommendations are updated, clinical trials are published, and a new look at pathogenetic mechanisms is made.
The prerequisites for holding of this Expert Forum were the updating of the FIGO classification of uterine bleeding in 2018, the NICE guidelines “Heavy menstrual bleeding: assessment and management” in 2018 and 2021, as well as the new conditions of the pandemic era, which has taken its toll on the care of patients with AUB.
The Resolution summarized all data unaccounted for in the current clinical protocol for AUB issued in 2016 and updated data from international guidelines and key studies in patients with AUB; highlighted in detail current thinking on the pathogenetic therapy of functional AUB, with an emphasis on chronic AUB associated with ovulatory dysfunction (AUB-O) and endometrial disorders (AUB-E), as the most common; provided modern approaches to the management of chronic AUB associated with non-structural causes (ovulatory dysfunction and endometrial factors), and prevention of acute AUB for implementation in clinical practice and improving the provision of evidence-based medical care and individualized patient care.
The Resolution aims to optimize clinical approaches to patient management and ensure therapy personalization, which together will improve the reproductive health and general well-being of Ukrainian women.


  1. Marret, H., Fauconnier, A., Chabbert-Buffet, N., et al. “Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause.” Eur J Obstet Gynecol Reprod Biol 152.2 (2010): 133–7.
  2. Podzolkova, N.M., Glazkova, O.L. Symptom, syndrome, diagnosis. Differential diagnosis in gynecology. 3rd ed., revised and add. Moscow. GEOTAR-Media (2014): 736 p.
  3. Munro, M.G., Critchley, H.O.D., Fraser, I.S. “The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.” Int J Gynecol Obstet 143.3 (2018): 393–40.
  4. Santer, M., et al. “What aspects of periods are most bothersome for women reporting heavy menstrual bleeding? Community survey and qualitative study.” BMC Women’s Health 7 (2007): 8.
  5. Kim, T., et al. “Associations of mental health and sleep duration with menstrual cycle irregularity: a population-based study.” Arch Women's Ment Health 21.6 (2018): 619–26.
  6. Savelyeva, G.M., Sukhikh, G.T., Serov, V.N., et al. Gynecology: national guidance. 2nd ed., revised and add. Moscow. GEOTAR-Media (2017): 1008 p.
  7. Solovyeva, A.V., Ermolenko, K.S. “Differntiated approach to choice of therapy in women with abnormal uterine bleeding.” Obstetrics and Gynecology 3 (2018): 157–60. DOI: 10.18565/aig.2018.3.157-160
  8. Law of Ukraine. “Fundamentals of Ukrainian legislation on health care” from 19.11.1992 No. 2801-XII.
  9. Ministry of Health of Ukraine. Order from 13.04.2016 No. 353. “About approval and introduction of medical and technological documents for standardization of medical care in abnormal uterine bleedings”.
  10. Munro, M.G., Critchley, H.O., Broder, M.S., Fraser, I.S. “FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age.” Int J Gynecol Obstet 113.1 (2011): 3–13.
  11. American College of Obstetricians and Gynecologists. “Committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women.” Obstet Gynecol 121.4 (2013): 891–6.
  12. NICE. Heavy menstrual bleeding: Assessment and management (NG88). London (2018). Last update 24 May 2021.
  13. NICE. Heavy Menstrual Bleeding. London: RCOG Press (2007).
  14. Practice Committee of the American Society for Reproductive Medicine. “Current clinical irrelevance of luteal phase deficiency: a committee opinion.” Fertil Steril 103.4 (2015): e27–32.
  15. Tatarchuk, T.F., Kosei, N.V., Tutchenko, T.N., Kapshuk, I.N. “Modern diagnosis and treatment of abnormal uterine bleeding.” Reproductive Endocrinology 1.3 (2012): 74–8.
  16. Khrouf, M., Terras, K. “Diagnosis and Management of Formerly Called “Dysfunctional Uterine Bleeding” According to PALM-COEIN FIGO Classification and the New Guidelines.” J Obstet Gynaecol India 64 (2014): 388–93. DOI: 10.1007/s13224-014-0641-1
  17. Sibirskaya, Е.V., Pivazyan, L.G. “Hormonal therapy for management of abnormal uterine bleeding in women of late reproductive age.” Gynecology, Obstetrics and Perinatology 19.2 (2020): 129–35. (In Russian). DOI: 10.20953/1726-1678-2020-2-129-135
  18. Dozortsev, D., et al. “Luteinizing hormone-independent rise of progesterone as the physiological trigger of the ovulatory gonadotropins surge in the human.” Fertil Steril 114.2 (2020): 191–9. DOI: 10.1016/j.fertnstert.2020.06.016
  19. Buchholz, R., Nocke, L., Nocke, W. “The influence of gestagens on the urinary excretion of pituitary gonadotropins, estrogens, and pregnanediol in women in the postmenopause and during the menstrual cycle.” Int J Fertil 9 (1964): 231–51.
  20. Liu, J.H., Yen, S.S. “Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation.” J Clin Endocrinol Metab 57 (1983): 797–802.
  21. Batista, M.C., Cartledge, T.P., Zellmer, A.W., et al. “Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation.” J Clin Endocrinol Metab 74 (1992): 565–70.
  22. Dangal, G. “Menstrual disorders in adolescents.” The Internet Journal of Gynecology and Obstetrics 4.1 (2005): Available from: [], accessed 14 May 2018.
  23. Pinkerton, J.A.V. “Pharmacological therapy for abnormal uterine bleeding.” Menopause 18.4 (2011): 453–61.
  24. Hickey, M., Higham, J.M., Fraser, I. “Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation.” Cochrane Database of Systematic Reviews 9 (2012): CD001895.
  25. Heikinheimo, O., Fraser, I. “The current status of hormonal therapies for heavy menstrual bleeding.” Best Pract Res Clin Obstet Gynaecol 40 (2017): 111–20.
  26. Davis, E., Sparzak, P.B. Abnormal Uterine Bleeding. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 Apr 1.
  27. World Health Organization. Medical eligibility criteria for contraceptive use – 5th ed (2015).
  28. Dubrovina, S.O., Kirevnina, L.V., Lesnoy, M.N. “Abnormal uterine bleeding: causes, diagnosis, and treatment.” Obstetrics and Gynecology 1 (2021): 170–7 (in Russian). DOI: 10.18565/aig.2021.1.170-177
  29. Lockwood, C.J. “Mechanisms of normal and abnormal endometrial bleeding.” Menopause 18.4 (2011): 408–11.
  30. Kuhl, H. “Pharmacology of estrogens and progestogens: influence of different routes of administration.” Climacteric 8.1 (2005): 3–63.
  31. Singh, S., Best, C., Dunn, S. “Abnormal uterine bleeding in pre-menopausal women. Clinical practice guideline No. 292.” J Obstet Gynaecol Can 35.5 (2013): 473–5.
  32. Tajjamal, A., Zaman, F. “Severity of bleeding is a predictor of quality of life in women with heavy menstrual bleeding under dydrogesterone treatment in a prospective, multicentre, observational study.” Gazz Med Ital 174.9 (2015): 391–8.
  33. Podzolkova, N., Tatarchuk, T., Doshchanova, A., et al. “Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study.” Gynecol Endocrinol 32.3 (2016): 246.
  34. Trivedi, N., Chauhan, N., Vaidya, V. “Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study.” Gynecol Endocrinol 32.8 (2016): 667–71.
  35. Mezhevitinova, E.A., Dovletkhanova, E.R. “Possibilities of dydrogesterone usage in women with insufficiency of the luteal phase of the menstrual cycle.” Gynecology 3 (2010): 18–25.
  36. Instruction for medical use Duphaston® 01.06.2020.
  37. Tatarchuk, T.F., Dubossarska, Z.M., Pyrohova, V.I., et al. “On the use of sex steroids in women during the COVID-19 pandemic. The consensus position statement of professional medical associations.” Reproductive Endocriniology 2.58 (2021). DOI: 10.18370/2309-4117.2021.58.9-16
  38. Schindler, A.E. “Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.” Maturitas 65 (2009): S3–11.



How to Cite

-, .-. (2021). Resolution of the 1st Ukrainian expert forum on abnormal uterine bleeding: On April 20, 2021, the Ukrainian Expert Forum on Abnormal Uterine Bleeding was held . REPRODUCTIVE ENDOCRINOLOGY, (62), 64–74.